Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.
about
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.Total aortic arch replacement: superior ventriculo-arterial coupling with decellularized allografts compared with conventional prosthesesFunctional Characterization of the GUCY1A3 Coronary Artery Disease Risk Locus.cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.Cardioprotective role of P38 MAPK during myocardial infarction via parallel activation of α-crystallin B and Nrf2.Acute ethanol exposure increases the susceptibility of the donor hearts to ischemia/reperfusion injury after transplantation in ratsCardioprotective Effects of Essential Oil of Lavandula angustifolia on Isoproterenol-induced Acute Myocardial Infarction in Rat.Soluble guanylate cyclase-α1 is required for the cardioprotective effects of inhaled nitric oxide.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Mediterranean diet and cardioprotection: the role of nitrite, polyunsaturated fatty acids, and polyphenols.The alpha1 isoform of soluble guanylate cyclase regulates cardiac contractility but is not required for ischemic preconditioningThe soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitusPathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling.Phytochemical screening and evaluation of cardioprotective activity of ethanolic extract of Ocimum basilicum L. (basil) against isoproterenol induced myocardial infarction in ratsRole of α-crystallin B as a regulatory switch in modulating cardiomyocyte apoptosis by mitochondria or endoplasmic reticulum during cardiac hypertrophy and myocardial infarction.Superiority of zinc complex of acetylsalicylic acid to acetylsalicylic acid in preventing postischemic myocardial dysfunction.Cinaciguat prevents the development of pathologic hypertrophy in a rat model of left ventricular pressure overload.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Allosteric regulation of nucleotidyl cyclases: an emerging pharmacological target.The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism.Role of sGC-dependent NO signalling and myocardial infarction risk.Myocardial protection from ischemia-reperfusion injury post coronary revascularization.Targeting vascular (endothelial) dysfunction.Cardioprotective Effect of Ulmus wallichiana Planchon in β-Adrenergic Agonist Induced Cardiac HypertrophyAcute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration.Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.A mouse model reveals an important role for catecholamine-induced lipotoxicity in the pathogenesis of stress-induced cardiomyopathy.Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity.Modulation of NFKB1/p50 by ROS leads to impaired ATP production during MI compared to cardiac hypertrophy.Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation.Influence of cinaciguat on gastrointestinal motility in apo-sGC mice.Administration of zinc complex of acetylsalicylic acid after the onset of myocardial injury protects the heart by upregulation of antioxidant enzymes.Graft preservation with heparinized blood/saline solution induces severe graft dysfunction.Cardioprotection by Intermittent Hypoxia Conditioning: Evidence, Mechanisms and Therapeutic Potential.
P2860
Q27692662-357BFF54-2976-402B-BB08-865824EF2263Q28541464-C4F65EC7-8760-4A45-B30B-75FBAECFC0ACQ30252419-E3F0CE21-5044-4DBA-8CA1-6AE36932CC12Q34244951-86A128E3-DC24-4471-8EF2-BAA0B3B9B063Q34400162-994905D6-6D8B-4964-875D-01B19131001EQ34479341-AD810C41-1DCA-4157-927F-9FBF72A7953CQ34777781-5438E879-EE16-4D81-BC38-8A6EB177DB27Q34784680-E3B89C63-66BE-4C90-966B-B8CAB64D556EQ35010064-1BE6D2BB-766D-4326-91A7-0E5F2C243F58Q35053534-FD0C4515-0F80-49DC-9CE9-520FD43C0F6CQ36031657-A8281B84-5954-4C1D-A779-6EE01DEA0193Q36234790-08B6E25E-3182-4714-9362-B7ABF2EE0820Q36532454-AD61C72D-36E7-42BE-96CE-615F4E865034Q36565025-7845B4B9-ABFE-4C5D-80E8-614452C7082DQ36809512-861FEFF6-787F-4B77-BCAF-1A333DB1A843Q37071400-948A580D-58B4-4704-961A-8FDB1BF44F69Q37419185-13FC84F6-9738-443B-A3B7-0AA969D38AC3Q38000562-59A8C70D-7C25-4317-9CB7-DCDB16254BA0Q38040779-E3A09243-5146-4350-84F5-58658DB06A1CQ38258238-D2D9EB26-FEEE-4900-A5BD-A5A76733BE81Q38367012-B51C6061-7A53-47DD-AF9F-7890216157C4Q38552442-B1BE1E69-DC4C-4B19-A98E-0B4C6AE4D7B7Q38836199-A99C3B69-FC4E-4DEF-B8D5-11AFA9C04777Q39576954-E451F5CA-67DE-4F55-8E12-D84B653E1B91Q41112375-EDA79E64-46C4-4973-ADE9-DDA7AD5C7653Q42075795-EBC1DB65-DEAE-46DE-AF6C-C76016A778C2Q42514867-743607A9-77A8-4E3B-BAA4-CF9C77EE88D5Q43074266-87DEB766-4B61-41B1-8153-BFA6DD560B2DQ46326335-E5B92124-4833-4882-93B6-42199FC06576Q47133234-85E07E8F-73D4-4B91-B54E-B11AA42769E8Q49047822-91C924C2-96F1-4D8F-B394-4737725BB519Q53469228-A0520D6D-494D-4F41-B9B5-CE874F2165DFQ53612348-E7BE8558-267F-4849-9912-A3BC873FB792Q53695762-14212B8F-A570-4C50-80F9-A97311AA807E
P2860
Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Pharmacological activation of ...... heart against ischemic injury.
@en
Pharmacological activation of ...... heart against ischemic injury.
@nl
type
label
Pharmacological activation of ...... heart against ischemic injury.
@en
Pharmacological activation of ...... heart against ischemic injury.
@nl
prefLabel
Pharmacological activation of ...... heart against ischemic injury.
@en
Pharmacological activation of ...... heart against ischemic injury.
@nl
P2093
P1433
P1476
Pharmacological activation of ...... heart against ischemic injury.
@en
P2093
Beatrice Seidel
Eniko Barnucz
Gábor Szabó
Gábor Veres
Kristóf Hirschberg
Matthias Karck
Philipp Neugebauer
Sevil Korkmaz
Sivakkanan Loganathan
Stefan Zöllner
P304
P356
10.1161/CIRCULATIONAHA.109.870774
P407
P577
2009-08-10T00:00:00Z